128 related articles for article (PubMed ID: 37960757)
21. Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.
Yu W; Yuan X; Ye F; Mao C; Li J; Zhang M; Chen D; Xia S
Immunotherapy; 2022 Nov; 14(16):1291-1296. PubMed ID: 36169194
[TBL] [Abstract][Full Text] [Related]
22. Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.
Santelmo C; Ravaioli A; Barzotti E; Papi M; Poggi B; Drudi F; Mangianti M; Salvi M; Crinò L
Lung Cancer; 2013 Aug; 81(2):294-6. PubMed ID: 23683537
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Miyauchi E; Inoue A; Kobayashi K; Maemondo M; Sugawara S; Oizumi S; Isobe H; Gemma A; Saijo Y; Yoshizawa H; Hagiwara K; Nukiwa T;
Jpn J Clin Oncol; 2015 Jul; 45(7):670-6. PubMed ID: 25877748
[TBL] [Abstract][Full Text] [Related]
24. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
25. Lung adenocarcinoma organoids harboring EGFR 19Del and L643V double mutations respond to osimertinib and gefitinib: A case report.
Bie Y; Wang J; Xiong L; Wang D; Liao J; Zhang Y; Lin H
Medicine (Baltimore); 2021 Mar; 100(11):e24793. PubMed ID: 33725945
[TBL] [Abstract][Full Text] [Related]
26. Current two EGFR mutations in lung adenocarcinoma - case report.
Svaton M; Pesek M; Chudacek Z; Vosmiková H
Klin Onkol; 2015; 28(2):134-7. PubMed ID: 25882025
[TBL] [Abstract][Full Text] [Related]
27. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
[TBL] [Abstract][Full Text] [Related]
30. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
31. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH
Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
[TBL] [Abstract][Full Text] [Related]
33. Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer.
Goto K; Shiraishi Y; Murakami H; Horinouchi H; Toyozawa R; Takeda M; Uno M; Crawford N; McGill J; Jimbo T; Ishigami M; Takayama G; Nakayama S; Ohwada S; Nishio M
Cancer Med; 2023 Mar; 12(6):7090-7104. PubMed ID: 36621830
[TBL] [Abstract][Full Text] [Related]
34. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
[TBL] [Abstract][Full Text] [Related]
35. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Yang JJ; Fang J; Shu YQ; Chang JH; Chen GY; He JX; Li W; Liu XQ; Yang N; Zhou C; Huang JA; Frigault MM; Hartmaier R; Ahmed GF; Egile C; Morgan S; Verheijen RB; Mellemgaard A; Yang L; Wu YL
Invest New Drugs; 2021 Apr; 39(2):477-487. PubMed ID: 33052556
[TBL] [Abstract][Full Text] [Related]
36. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
37. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Tamura T; Kawakado K; Makimoto G; Nakanishi M; Kuyama S
Thorac Cancer; 2021 Jun; 12(11):1770-1774. PubMed ID: 33942527
[TBL] [Abstract][Full Text] [Related]
38. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
[TBL] [Abstract][Full Text] [Related]
39. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
[TBL] [Abstract][Full Text] [Related]
40. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Kozlov V; Karpov I; Kovalenko S; Shamanin V
Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
